🔍 Search
PreventionIARC class 1N/A (epidemiology)

Sunbed exposure

Tanning beds; tanning lamps; commercial UV tanning

Sunbed exposure is an IARC Group 1 carcinogen — the highest classification, alongside tobacco and asbestos. Use is associated with a substantial increase in melanoma risk (relative risk ~ 1.2 with any use; ~ 1.6 with use before age 35), with the strongest dose-response in young users. UK legislation (Sunbeds Regulation Act 2010) bans use by under-18s and mandates information provision and exposure controls in commercial premises. There is essentially no clinical indication for commercial sunbed use; UVB phototherapy under dermatological supervision is a different therapeutic intervention.

CurrentLast reviewed 15 May 2026

Risk evidence

  • IARC Monograph 100D (2012) — sunbeds classified Group 1 carcinogen (sufficient evidence in humans).
  • Boniol et al. (BMJ 2012, meta-analysis) — any sunbed use associated with ~ 20% increase in melanoma risk; use before age 35, ~ 60% increase (RR ~1.59; Boniol 2012 published correction). Each additional sunbed session before 35 adds ~ 2% relative risk.
  • NMSC — clear association with cSCC and BCC, particularly in young users.
  • Ocular melanoma — increased risk; eye protection mandatory but often inadequately used.
  • Skin ageing, immunosuppression, eye damage — all additional harms.

UK regulation

  • Sunbeds (Regulation) Act 2010 — bans use, sale and hire to under-18s in commercial premises in England and Wales (separate equivalent legislation in Scotland and Northern Ireland).
  • Enforcement by local authority trading standards; £20 000 maximum fine.
  • Operators must provide written information about health risks, offer protective eyewear, supervise sessions.
  • No safety standard exists for "safe" sunbed use; no recommended dose.
  • Private home sunbed use is not legislated — public health concern.

Patient counselling

  • Direct advice — there is no safe level of sunbed use. Tanning is itself evidence of UV damage.
  • Address common misconceptions:
    • "It's a controlled dose" — not safer than the sun; sunbeds deliver UV at levels exceeding tropical midday sun.
    • "It builds protection / base tan" — minimal protection (SPF 3–4 equivalent) at the cost of substantial DNA damage.
    • "It boosts vitamin D" — see vitamin D; supplementation is safer and more reliable.
  • For patients with a history of skin cancer, sunbeds should be explicitly discouraged.

Distinction from medical phototherapy

  • UVB and PUVA phototherapy under dermatological supervision (for psoriasis, eczema, vitiligo, CTCL) are different interventions:
    • Narrowband UVB (311 nm) chosen for therapeutic ratio.
    • Cumulative dose tracked; lifetime limits applied (e.g. 200–250 sessions for PUVA).
    • Carries skin-cancer risk but balanced against disease benefit.
  • Sunbed use does not provide controlled therapeutic UVB and is not a substitute.

References

  1. IARC Monograph 100D; 2012.
  2. Boniol M et al. Cutaneous melanoma attributable to sunbed use — systematic review and meta-analysis. BMJ; 2012;345:e4757.
  3. Sunbeds (Regulation) Act 2010 (England and Wales).
  4. NICE NG34. Sunlight exposure: risks and benefits. London: NICE; 2016.

Spot a correction?

If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.